

December 9, 2011



VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement

SINGAPORE, Dec. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it will issue US\$1,110,000 worth of shares of its common stock to AIM-listed company, ValiRx PLC. The share issuance is the final requirement of the Share Purchase Agreement dated 22 September 2010 (as amended on 9 June 2011) between ValiRx and Singapore Volition Pte Limited, a subsidiary of VolitionRX.

Volition will issue 525,000 restricted shares of common stock to ValiRx. Of that number of shares, 14,189 shares will be issued directly to Chroma Therapeutics Limited of Abingdon, Oxfordshire, UK, as payment for the direct licensing of Chroma Therapeutics's patent "*Detection Of Histone Modifications In Cell-Free Nucleosomes*" to Singapore Volition.

Cameron Reynolds, CEO of VolitionRX, said, "We're grateful to ValiRx for their advice and support over the last 15 months, and are therefore delighted to make this final payment of shares to ValiRx. We're also happy to be issuing shares as royalty to Chroma Therapeutics, whose patent forms a significant part of our technology portfolio."

About VolitionRX

[VolitionRX is a life sciences company](#) whose goal is to make its [non-invasive blood tests for cancer](#) as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRX [is managed](#) by a well-respected team with extensive experience in diagnostics and commercialization. VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

VolitionRX is quoted on the OTC Bulletin Board in the United States of America, under the symbol VNRX.OB.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those

described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE VolitionRX Limited